Literature DB >> 19673631

Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.

Naim Alkhouri1, Laura J Dixon, Ariel E Feldstein.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease affecting both adults and children in the USA and many other parts of the world. NAFLD encompasses a wide spectrum of conditions associated with the overaccumulation of lipids in the liver, ranging from steatosis to nonalcoholic steatohepatitis, to cirrhosis and its feared complications of portal hypertension, liver failure and hepatocellular carcinoma. In this article, we will focus on the growing evidence linking changes in hepatic lipid metabolism and accumulation of specific lipid types in the liver with hepatocellular damage, inflammation and apoptosis, resulting in disease progression to the more serious forms of this condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673631      PMCID: PMC2775708          DOI: 10.1586/egh.09.32

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  43 in total

Review 1.  Mitochondria: pharmacological manipulation of cell death.

Authors:  Lisa Bouchier-Hayes; Lydia Lartigue; Donald D Newmeyer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4.

Authors:  Gyongyi Szabo; Arumugam Velayudham; Laszlo Romics; Pranoti Mandrekar
Journal:  Alcohol Clin Exp Res       Date:  2005-11       Impact factor: 3.455

3.  TLR4 links innate immunity and fatty acid-induced insulin resistance.

Authors:  Hang Shi; Maia V Kokoeva; Karen Inouye; Iphigenia Tzameli; Huali Yin; Jeffrey S Flier
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

4.  Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis.

Authors:  Harmeet Malhi; Steven F Bronk; Nathan W Werneburg; Gregory J Gores
Journal:  J Biol Chem       Date:  2006-02-27       Impact factor: 5.157

5.  Sphingolipid signalling and liver diseases.

Authors:  Montserrat Marí; José C Fernández-Checa
Journal:  Liver Int       Date:  2007-05       Impact factor: 5.828

6.  Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis.

Authors:  Montserrat Marí; Francisco Caballero; Anna Colell; Albert Morales; Juan Caballeria; Anna Fernandez; Carlos Enrich; José C Fernandez-Checa; Carmen García-Ruiz
Journal:  Cell Metab       Date:  2006-09       Impact factor: 27.287

Review 7.  Ceramides in insulin resistance and lipotoxicity.

Authors:  Scott A Summers
Journal:  Prog Lipid Res       Date:  2005-12-19       Impact factor: 16.195

Review 8.  Sphingolipids and cell death.

Authors:  Albert Morales; Hyunmi Lee; Felix M Goñi; Richard Kolesnick; José C Fernandez-Checa
Journal:  Apoptosis       Date:  2007-05       Impact factor: 4.677

9.  Bax inhibition protects against free fatty acid-induced lysosomal permeabilization.

Authors:  Ariel E Feldstein; Nathan W Werneburg; Zhengzheng Li; Steven F Bronk; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-02-16       Impact factor: 4.052

10.  Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells.

Authors:  Yuren Wei; Dong Wang; Farran Topczewski; Michael J Pagliassotti
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-02-21       Impact factor: 4.310

View more
  150 in total

1.  Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.

Authors:  Masayuki Nagahashi; Kazuaki Takabe; Runping Liu; Kesong Peng; Xiang Wang; Yun Wang; Nitai C Hait; Xuan Wang; Jeremy C Allegood; Akimitsu Yamada; Tomoyoshi Aoyagi; Jie Liang; William M Pandak; Sarah Spiegel; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

2.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

3.  A hedgehog survival pathway in 'undead' lipotoxic hepatocytes.

Authors:  Keisuke Kakisaka; Sophie C Cazanave; Nathan W Werneburg; Nataliya Razumilava; Joachim C Mertens; Steve F Bronk; Gregory J Gores
Journal:  J Hepatol       Date:  2012-05-26       Impact factor: 25.083

4.  Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.

Authors:  Naim Alkhouri; Arthur J McCullough
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

5.  Cysteine aggravates palmitate-induced cell death in hepatocytes.

Authors:  Xiaobing Dou; Zhigang Wang; Tong Yao; Zhenyuan Song
Journal:  Life Sci       Date:  2011-10-08       Impact factor: 5.037

Review 6.  An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

Authors:  Frank J Gonzalez; Changtao Jiang; Andrew D Patterson
Journal:  Gastroenterology       Date:  2016-09-14       Impact factor: 22.682

Review 7.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

Review 8.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

9.  Lin28 enhances de novo fatty acid synthesis to promote cancer progression via SREBP-1.

Authors:  Yang Zhang; Chenchen Li; Chuanzhen Hu; Qian Wu; Yongping Cai; Songge Xing; Hui Lu; Lin Wang; Linchong Sun; Tingting Li; Xiaoping He; Xiuying Zhong; Junfeng Wang; Ping Gao; Zachary J Smith; Weidong Jia; Huafeng Zhang
Journal:  EMBO Rep       Date:  2019-08-05       Impact factor: 8.807

10.  Up-regulation of stearoyl-CoA desaturase 1 increases liver MUFA content in obese Zucker but not Goto-Kakizaki rats.

Authors:  Minako Karahashi; Fumiko Ishii; Tohru Yamazaki; Koichi Imai; Atsushi Mitsumoto; Yoichi Kawashima; Naomi Kudo
Journal:  Lipids       Date:  2013-03-29       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.